Loading clinical trials...
Loading clinical trials...
Description of the Changes of Ocular Perfusion in Patients with Age-related Maculopathy or Diabetic Macula Edema After Intravitreal Aflibercept Injection Treatment
This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. Ocular perfusion will be measured by Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR will be measured at the optic nerve head (ONH). The devices software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas (MT) separately. Measurements will be conducted on the day of the planned intravitreal injection and one and four weeks post-injection.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Department for Ophthalmology
Linz, Upper Austria, Austria
Start Date
November 22, 2023
Primary Completion Date
June 29, 2024
Completion Date
July 30, 2024
Last Updated
March 17, 2025
36
ACTUAL participants
Intravitreal Aflibercept Injection
DRUG
Laser speckle flowgraphy
DEVICE
Lead Sponsor
Augenabteilung Allgemeines Krankenhaus Linz
NCT07449936
NCT07449923
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions